Bristol-Myers Squibb Company Website

Bristol-Myers Squibb Company

NYSE-BMY

Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

  • Name

    Bristol-Myers Squibb Company

  • CEO

    Christopher S. Boerner

  • Website

    www.bms.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1887

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Bristol is launching innovative drugs in cardiology and neurology, which should have strong sales trajectories given the high unmet medical need.

  • We forecast oncology drug Opdivo should see annual peak sales of more than $10 billion, helping to fuel development costs for the next generation of drugs.

  • The majority of Bristol's late-stage pipeline focuses on rare diseases, immunology, and cancer, where drug firms hold strong pricing power and the Food and Drug Administration aggressively approves new therapies.

Bears Say

  • The acquisition of Celgene came shortly before the start of generic competition for Celgene's cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.

  • Bristol faces one of the larger patent cliffs by 2028, when cancer drug Opdivo and cardiovascular drug Eliquis likely face heavy generic competition.

  • The Celgene acquisition added significant debt that could become challenging to repay if competition strengthens against key drugs or pricing pressures intensify in the US.

Source: Morningstar Analysis - Nov 03, 2025

What's happening

Nov 12, 2025 - Dec 12, 2025

Bristol-Myers Squibb Co. Surges Amid Strategic Advances and Dividend Growth

  • Bristol-Myers Squibb Co. raised its quarterly dividend, marking 17 consecutive years of increases.
  • The approval of Breyanzi as a CAR T cell therapy enhances BMY's oncology portfolio.
  • Clinical trial results alongside BioNTech show promise against aggressive breast cancer types.

Over the past month, Bristol-Myers Squibb Co. (BMY) experienced a price increase of 5.1%, significantly outperforming the S&P 500's return of 0.7%. This performance indicates BMY's resilience and growth potential in a challenging market environment, especially as it surpassed the Health Care sector by 3.2%. Several bullish developments contributed to this upward trajectory.

Key announcements included an increase in quarterly dividends from $0.62 to $0.63 per share, reinforcing investor confidence in BMY’s financial stability after achieving its 17th consecutive year of dividend increases. Analysts also raised their price targets for BMY; Wells Fargo adjusted its target from $53 to $55 due to optimism surrounding ongoing product advancements and pipeline progress.

The approval of Breyanzi as a CAR T cell therapy for adults with relapsed or refractory marginal zone lymphoma further bolstered sentiment around BMY's innovative capabilities in oncology treatments. Additionally, promising clinical trial results involving therapies developed alongside BioNTech indicated significant effectiveness against aggressive breast cancer types, showcasing strong data that could enhance future sales prospects.

Despite some setbacks such as the discontinuation of the Phase 3 Librexia ACS trial due to concerns over efficacy endpoints—leading to temporary declines on certain days—overall investor sentiment remained positive due to strategic initiatives aimed at expanding treatment options and improving patient access through collaborations with research institutes.

In summary, Bristol-Myers Squibb Co.'s robust performance over this one-month period reflects solid operational execution amid favorable market conditions despite facing challenges related to specific trials or legal issues while clearly distinguishing itself positively compared to both sector peers and general market indices.

NYSE:BMY